{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"description":"Overall survival - Percentage of Participants Alive at 12 Months","groups":[{"description":"Melphalan 100mg/m2/day iv days -2 and -1\n\nMelphalan: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.","id":"OG000","title":"Arm A (Mel)"},{"description":"Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3\n\nMelphalan: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.\n\nBendamustine: High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.","id":"OG001","title":"Arm B (BenMel)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}